Sirnaomics Ltd. (2257.HK)
| Previous Close | 7.310 |
| Open | 8.300 |
| Bid | 7.120 x N/A |
| Ask | 7.230 x N/A |
| Day's Range | 7.010 - 8.300 |
| 52 Week Range | 5.640 - 59.000 |
| Volume | |
| Avg. Volume | 3,449,599 |
| Market Cap | 623.986M |
| Beta (5Y Monthly) | -0.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.060 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 72.04 |
PR NewswireSirnaomics Announces 2023 Annual Results
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited annual results for the year ended 31 December 2023 (the "Year").
PR NewswireSirnaomics will Present its Innovative Dual-Targeted GalNAc muRNA Programs in 2024 OPT Conference
Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, will present its preclinical and clinical development of its GalAhead™ technology-based programs, focusing on an innovative dual-targeted-GalNAc design, muRNA platform drug candidates, at the upcoming 2024 OPT (Oligonucleotide & mRNA Therapeutics) Congress, which took place in Bosto
PR NewswireSirnaomics to Present Latest Developments of STP705 for Focal Fat Reduction at IMCAS World Congress 2024
Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, presented the latest developments on Polypeptide Nanoparticle (PNP) platform, and its pipeline program STP705 for Focal Fat Reduction's positive clinical data, at IMCAS World Congress 2024, which is taking place in Paris from February 1st - 3rd, 2024.
